USFDA conducted an inspection at Zydus Lifesciences Limited's manufacturing facility SEZ-1 at Pharmez, Ahmedabad from March 20 to March 24, 2023, the company announced through an exchange filing. The inspection was a pre-approval inspection (PAI) and a GMP Audit that concluded with three observations.
The company said that there were no data integrity related observations and the company is addressing these observations.
Zydus received final approval from USFDA for Lubiprostone Capsules, the company announced on March 24.
Zydus Lifesciences shares
Indian Auto Components Supplier ZF Commercial Vehicle Secures Mandate From E-Mobility Manufacturer To Develop Advanced Driver
Pakistan Forced To Sell Pakistan International Airlines Under IMF Pressure; Asim Munir-Linked Fauji Firm Among Final Bidders
Flipkart Appoints Master Of Digital Commerce, Dan Neary, To Its Board, Reflecting Commitment To Propelling Next Phase Of Growth
Ministry Of Road Transport Launches Special Drive For Identification & Removal Of Unauthorised Occupation On National Highways
The shares of Zydus Lifesciences on Friday closed at Rs 480.05, down by 0.47 per cent.
